CL 88236: RN given refers to parent cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 135010 |
SCHEMBL ID | 2599287 |
MeSH ID | M0054664 |
Synonym |
---|
34839-13-9 |
6h2e3oxb13 , |
1-amino-3-chloro-2-propanol hydrochloride, (s)- |
unii-6h2e3oxb13 |
(s)-1-amino-3-chloro-2-propanol hydrochloride |
2-propanol, 1-amino-3-chloro-, hydrochloride, (s)- |
cl 88236 |
(-)-1-amino-3-chloro-2-propanol hydrochloride |
(2s)-1-amino-3-chloropropan-2-ol hydrochloride |
AKOS016011935 |
(s)-1-amino-3-chloropropan-2-ol hydrochloride |
(2s)-1-amino-3-chloro-2-propanol hydrochloride |
ZCPJBHYNOFIAPJ-AENDTGMFSA-N |
SCHEMBL2599287 |
J-502361 |
2-propanol, 1-amino-3-chloro-, hydrochloride, (2s)- |
AC-26415 |
mfcd09056870 |
2-propanol, 1-amino-3-chloro-, hydrochloride (1:1), (2s)- |
1-amino-3-chloro-2-propanol hydrochloride, (-)- |
cl-88236 |
1-amino-3-chloro-2-propanol hydrochloride, (2s)- |
CS-W021152 |
(2s)-1-amino-3-chloropropan-2-ol hydrochloride (1:1) |
(2s)-1-amino-3-chloro-propan-2-ol hydrochloride |
AS-10252 |
AMY31075 |
Q27264905 |
(2s)-1-amino-3-chloropropan-2-ol;hydrochloride |
(s)-1-amino-3-chloro-2-propanol hcl |
F14970 |
(s)-1-amino-3-chloropropan-2-olhydrochloride |
EN300-1717672 |
Excerpt | Relevance | Reference |
---|---|---|
"Male Wistar Strain rats of known fertility were given subcutaneous dosage of three drugs, alpha-chlorohydrin, amino-alpha-chlorohydrin, and busulphan alone or in combination for a period of thirty days." | ( Agonistic properties of low doses of antifertility compounds in male rats. Hafez, ES; Shandilya, LN; Snydle, FE, 1979) | 0.26 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 6 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |